logo-loader
viewGenprex, Inc.

Genprex closes on $8M at-the-market stock offering

It intends to use the money to advance its lead clinical programs in non-small cell lung cancer

Genprex, Inc. - Genprex closes on $8M at-the-market stock offering
Genprex sold 7.6 million shares at a price of $1.05 per share

Genprex Inc (NASDAQ:GNPX) announced Tuesday that it has closed on an at-the-market stock offering that raised $8 million.  

The gene therapy company sold 7.6 million shares at a price of $1.05 per share, in accordance with Nasdaq rules governing registered direct offerings. No warrants were issued in the offering. 

Genprex, based in Austin, Texas and Cambridge, Massachusetts, intends to use the net proceeds to advance its lead clinical programs in non-small cell lung cancer (NSCLC) and for working capital and general corporate purposes. 

READ: Genprex wins FDA Fast Track status for its Oncoprex therapy in combination with AstraZeneca's Tagrisso

“The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors,” said CEO Rodney Varner in a statement.

“This offering significantly improves our balance sheet and allows us the financial flexibility to further develop our pipeline and advance our clinical trials in NSCLC for our lead drug candidate, Oncoprex, in combination with already approved lung cancer therapies. We are excited to generate additional clinical data in NSCLC from Oncoprex’s novel mechanisms of action.”

Genprex’s stock recently rose 13% to $1.38 a share in pre-market trading. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Genprex, Inc.

Price: 5.33 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $148.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CEO Rodney Varner sees newly licensed therapy as an...

 (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed therapy was an 'opportunity we...

1 week, 3 days ago

2 min read